Another insider at Scribe Therapeutics, Inc. (SCTX) has stepped into the open market with a sizable purchase. According to a Form 4 filed with the SEC, AH Bio Fund II, L.P. bought 333,333 shares of the gene-editing biotech on July 27, 2026, paying $15.00 per share for a total outlay of $4,999,995.00.
The transaction is coded as an open-market purchase, meaning AH Bio Fund II used its own capital to acquire the stake rather than receiving shares through options, grants, or other compensation-related mechanisms. Following the purchase, the fund’s holdings stand at 2,385,075 shares, which the filing lists as held indirectly, consistent with ownership through a fund or affiliated entity rather than a direct personal account.
People searching for how to see insider trading activity often land on filings like this one because the mechanics are straightforward: a fund, executive, or director puts several million dollars of its own money into shares at a fixed price, disclosed publicly within days of the trade. There’s no ambiguity about intent to profit from options or hedge exposure here — it’s a straight cash-for-stock transaction at the market’s going rate.
Part of a Broader Pattern at Scribe
This purchase did not happen in isolation. The same filing date, July 27, 2026, also produced a separate disclosure covering an OrbiMed-affiliated director buying $15 million worth of SCTX shares, detailed in our earlier report, SCTX Insider Buy: OrbiMed Director Buys $15M in Shares. Taken together, the two disclosures suggest multiple insiders were willing to commit substantial capital to Scribe Therapeutics stock within the same trading session.
Academic research on insider trading patterns has found that clustered buying — multiple insiders purchasing shares independently around the same period — tends to correlate statistically with subsequent outperformance more reliably than a single isolated purchase. That said, this correlation is a historical market observation and not a signal specific to this filing, nor is it a suggestion about what any individual investor should do with SCTX shares.
For now, the filing simply confirms the facts: AH Bio Fund II spent just under $5 million to acquire 333,333 shares of Scribe Therapeutics at $15.00 each, bringing its indirect stake to over 2.38 million shares as of the transaction date.
Source: original SEC Form 4 filing.